Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies
View Patent ↗The subject invention relates to methods for improving a subject's vasculature to normalize maternal hemodynamics, particularly in subjects attempting to conceive via assisted reproductive technologies, and comprises increasing relaxin levels in a subject or increasing any one or more of: relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, or relaxin receptor activity.
1. A method for improving cardiovascular adaptations in a subject attempting to conceive via an assisted reproductive technology (ART) and for improving cardiovascular adaptations to pregnancy in the subject during gestation, wherein improving cardiovascular adaptations is any one or combination of: cardiac output, systemic vascular resistance (SVR), mean arterial pressure, or glomerular filtration rate, wherein said method comprises administering to the subject an amount of relaxin agonist that is effective in promoting cardiovascular adaptations of pregnancy, and monitoring thereafter improvements in cardiovascular adaptations in the subject;
wherein the relaxin agonist binds to and activates the relaxin receptor to promote cardiovascular adaptations of pregnancy of the subject, wherein the relaxin agonist is a human relaxin polypeptide and the relaxin agonist is a polypeptide having at least 90% sequence identity to a relaxin polypeptide selected from human, pig, and rat relaxin;
wherein the human relaxin polypeptide comprises H2 relaxin having an A chain of SEQ ID NO: 7 and a B chain of SEQ ID NO: 8, or SEQ ID NO: 9; the pig relaxin polypeptide has an A chain of SEQ ID NO: 1 and a B chain of SEQ ID NO: 2; and the rat relaxin polypeptide has an A chain of SEQ ID NO: 3 and a B chain of SEQ ID NO: 4;
wherein the relaxin agonist is administered to the subject in late luteal phase and continued through at least the first trimester, and wherein monitoring thereafter improvements in cardiovascular adaptations in the subject consists of anyone or combination of: measuring cardiac output, calculating SVR, measuring mean arterial pressure, or measuring glomerular filtration rate.
2. The method of claim 1 , wherein the administration is by injection, intravenous delivery, subcutaneous delivery or oral delivery.
3. The method of claim 2 , wherein the administration is subcutaneous infusion.
4. The method of claim 1 , wherein the relaxin agonist is effective in improving fetal implantation, placentation, uteroplacental vasculature, fetoplacental vasculature, and/or fetal vasculature.
5. The method of claim 1 , wherein the relaxin agonist is effective in promoting healthy pregnancy and successful birth.
6. The method of claim 1 , wherein a therapeutically effective amount of at least one compound produced by corpus luteum (CL), other than relaxin, is administered with the relaxin agonist.
7. The method of claim 6 , wherein the compound produced by CL is selected from the group consisting of: androgens, estrogen, progesterone, inhibin A, and vasoendothelial growth factors.
8. The method of claim 1 , wherein the subject is administered the relaxin agonist as part of a luteal support regimen administered to women who are to receive ART.
9. The method of claim 1 , wherein the subject is administered the relaxin agonist beyond the first trimester.
10. The method of claim 1 , wherein administration of relaxin agonist also results in promotion of proper decidualization.
11. The method of claim 1 , wherein administration of relaxin agonist also results in promotion of trophoblast invasion of uterine spiral arteries.
12. The method of claim 1 , wherein administration of relaxin agonist also results in increased uterine blood flow.
13. A method for improving cardiovascular adaptations in a subject attempting to conceive via an assisted reproductive technology (ART) and for improving cardiovascular adaptations to pregnancy in the subject during gestation, wherein improving cardiovascular adaptations is anyone or combination of: cardiac output, systemic vascular resistance (SVR), mean arterial pressure, or glomerular filtration rate, wherein said method comprises administering to the subject an amount of a relaxin agonist that is effective in promoting cardiovascular adaptations of pregnancy, and monitoring thereafter improvements in cardiovascular adaptations in the subject;
wherein the relaxin agonist is a polypeptide having at least 90% sequence identity to human, pig, or rat relaxin polypeptide, wherein the human relaxin polypeptide comprises H2 relaxin having an A chain of SEQ ID NO: 7 and a B chain of SEQ ID NO: 8, or SEQ ID NO: 9: the pig relaxin polypeptide has an A chain of SEQ ID NO: 1 and a B chain of SEQ ID NO: 2: and the rat relaxin polypeptide has an A chain of SEQ 10 NO: 3 and a B chain of SEQ 10 NO: 4; wherein the relaxin agonist is administered to the subject in late luteal phase and continued through at least the first trimester, and
wherein monitoring thereafter improvements in cardiovascular adaptations in the subject consists of anyone or combination of: measuring cardiac output, calculating SVR, measuring mean arterial pressure, or measuring glomerular filtration rate.